Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study
Authors' conclusion
Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence.
Study context
- Population
- Diabetic patients on metformin-included combination antiglycemic therapy, National Health Insurance Research Database; excluded metformin contraindication, severe diabetic complications, poor drug compliance31,384 matched pairs
- Exposure
- Metformin adherence vs nonadherence
- Outcome
- Diagnosis of dementia or PD
- Follow-up
- Average 5 years
Methodological detailspropensity score matching
- Propensity score matching
Main finding
As reported in the abstract
Dementia
Metformin adherence associated with significantly lower risk of dementia, adjusted hazard risk ratio
0.72
P < .001
Observational data: associations, not effects.
Further findings
Parkinson's disease (PD) · average follow-up 5 years
- Metformin adherence not associated with lower risk of PD, adjusted hazard risk ratio
- 0.97, P = .825
Dementia by subgroup (sex, age >65 or ≤ 65 years, concurrent insulin)
- Dementia risk significantly reduced in metformin-adherent patients, both male and female, aged >65 or ≤ 65 years, and with or without concurrent insulin; effect not influenced by concurrent insulin
Original publication
Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study. Endocr Pract. Published 16 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →